Biosimilars of Humira have now launched, while biosimilars of Stelara are on the horizon. With a high concentration and dual pricing, Novartis and Sandoz’s Hyrimoz enjoys broad coverage across multiple national formularies despite not having an interchangeability designation, while Alvotech’s Humira biosimilar Simlandi has gained an approval from the FDA with interchangeability designation for its high-strength formula. Amgen’s Wezlana, the first approved Stelara biosimilar, is anticipated to launch on 1 January 2025. 

There are relatively few drugs in the pipeline for psoriatic arthritis, with many labels being extensions from other indications such as psoriasis. 

This Datamonitor Healthcare report contains a Disease Analysis module.